IL-13 receptor-directed cancer vaccines and immunotherapy

Immunotherapy. 2012 Apr;4(4):443-51. doi: 10.2217/imt.12.28.

Abstract

Many immunotherapy approaches including therapeutic cancer vaccines targeting specific tumor-associated antigens are at various stages of development. Although the significance of overexpression of (IL-13Rα2) in cancer is being actively investigated, we have reported that IL-13Rα2 is a novel tumor-associated antigen. The IL-13Rα2-directed cancer vaccine is one of the most promising approaches to tumor immunotherapy, because of the selective expression of IL-13Rα2 in various solid tumor types but not in normal tissues. In this article, we will summarize its present status and potential strategies to improve IL-13Rα2-directed cancer vaccines for an optimal therapy of cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Cancer Vaccines / genetics
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Immunosuppression Therapy
  • Immunotherapy / methods*
  • Immunotoxins / administration & dosage
  • Immunotoxins / immunology*
  • Interleukin-13 Receptor alpha2 Subunit / genetics
  • Interleukin-13 Receptor alpha2 Subunit / immunology*
  • Interleukin-13 Receptor alpha2 Subunit / metabolism
  • Lymphocyte Activation
  • Mice
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology
  • Vaccines, DNA / therapeutic use

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Immunotoxins
  • Interleukin-13 Receptor alpha2 Subunit
  • Vaccines, DNA